COVAXIN shows safety, immunogenicity in children aged 2-18 years: Lancet
Peer-reviewed data has been published in Lancet Infectious Diseases; phase II-III study was held to evaluate safety, and immunogenicity of COVAXIN among healthy children and adolescents.
